---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-030103"
form_type: "8-K"
ticker: "ATXI"
cik: "0001644963"
company_name: "AVENUE THERAPEUTICS, INC."
filed_at: "2023-03-08T23:59:59+00:00"
generated_at: "2026-06-18T08:32:25.529226+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Avenue Therapeutics schedules Type C FDA meeting for IV Tramadol; appoints MacLean to board, Kranzler Chairman

## Summary
- Type C FDA meeting on March 9, 2023 to discuss IV Tramadol respiratory depression study protocol; update expected April 2023.
- Board expanded to six; CEO Alexandra MacLean appointed director; Jay Kranzler named Chairman, Lindsay Rosenwald remains director.
- Annual meeting set for June 22, 2023; record date April 25, 2023; stockholder proposal deadline March 24, 2023.
- FDA previously agreed on study design aspects in August 2022 Type A meeting for IV Tramadol.

## SEC filing metadata
- accession: 0001104659-23-030103
- form_type: 8-K
- ticker: ATXI
- cik: 0001644963
- company_name: AVENUE THERAPEUTICS, INC.
- filed_at: 2023-03-08T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 5.08, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1644963/000110465923030103/0001104659-23-030103-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1644963/000110465923030103/tm238871d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-030103
- JSON: https://secwatch.observer/filing/0001104659-23-030103.json
- Plain text: https://secwatch.observer/filing/0001104659-23-030103.txt

## Key facts
- Executive change
  Jay Kranzler was appointed as Chairman of the Board at AVENUE THERAPEUTICS, INC..
  - Action: appointed
  - Role: Chairman of the Board
  source text: appointed Jay Kranzler, M.D., Ph.D. to serve as Chairman of the Board, effective immediately
  evidence_url: https://www.sec.gov/Archives/edgar/data/1644963/000110465923030103/0001104659-23-030103-index.htm
- Executive change
  Alexandra MacLean was appointed as Director at AVENUE THERAPEUTICS, INC..
  - Action: appointed
  - Role: Director
  source text: appointed Alexandra MacLean, M.D., Chief Executive Officer of the Company, to the Board as a director, effective immediately
  evidence_url: https://www.sec.gov/Archives/edgar/data/1644963/000110465923030103/0001104659-23-030103-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.